AIO-Studien-gGmbH

• Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden

  Phase 3, Not yet recruiting, 230 people, 20 Jul 2026

• NCT03473574

  Phase 2, Completed, 128 people, 22 Mar 2018

• NCT03345810

  Phase 2, Completed, 200 people, 17 Nov 2017

• NCT03317457

  Phase 2, Completed, 103 people, 23 Oct 2017

• NCT03193931

  Phase 2, Terminated, 47 people, 21 Jun 2017

• NCT03044587

  Phase 2, Completed, 93 people, 7 Feb 2017

• NCT03043729

  Phase 2, Completed, 119 people, 6 Feb 2017

• NCT02326285

  Phase 2/3, Terminated, 1 person, 29 Dec 2014

• NCT02128243

  Phase 2, Completed, 242 people, 1 May 2014

• NCT02113800

  Phase 2, Completed, 40 people, 15 Apr 2014

• NCT01991873

  Phase 2, Completed, 387 people, 25 Nov 2013

• NCT01668498

  Phase 2, Completed, 88 people, 20 Aug 2012

• NCT01627379

  Phase 3, Terminated, 300 people, 25 Jun 2012

• NCT01520103

  Phase 2, Completed, 139 people, 27 Jan 2012

• NCT01504256

  Phase 2, Completed, 42 people, 5 Jan 2012

• NCT01472029

  Phase 2, Completed, 53 people, 16 Nov 2011

• NCT01328171

  Phase 2, Completed, 93 people, 4 Apr 2011

• NCT00973609

  Phase 3, Completed, 853 people, 9 Sept 2009

• NCT00950820

  Phase 2, Terminated, 9 people, 3 Aug 2009

• NCT00889343

  Phase 2, Terminated, 101 people, 28 Apr 2009

Sources: clinicaltrials.gov